Management
Administratively HiLIFE is a research institute independent of the University’s faculties, the director of which is directly accountable to the Rector.

HiLIFE is regulated by University regulations and HiLIFE-specific Rules of Procedure. Director is  responsible for HiLIFE strategic plans, overall budget and human resources plan, and overseeing organization of evaluation of HiLIFE activities by HiLIFE Scientific Council. The Board, also nominated by the Rector, together with the director develops Institute's activities in accordance with the University’s strategy and recommendations of the Scientific Council that evaluates HiLIFE activities and organization in the context of the university, and provides recommendations on future plans and scientific directions.

HiLIFE contains the Institute for Molecular Medicine Finland FIMM, Institute of Biotechnology (BI) and Neuroscience Center (NC) as units. Unit (BI/FIMM/NC) directors are responsible for their unit’s daily operations. Management team composed of HiLIFE director, unit directors, 1-4 experts on HiLIFE’s umbrella activities and the Head of administration supports the director in preparing, implementing, and monitoring matters and decisions, and in internal and external communication and collaboration.

HiLIFE’s leadership and staff are supported by University Services so that academic community can focus on research, teaching, studying and public engagement.

HiLIFE Director Olli Silvennoinen

HiLIFE Director Olli Silvennoinen has overall responsibility of operations according to the University Regulations and HiLIFE Rules of Procedure and prepares matters for the Board.  Olli's research focuses on molecular mechanisms of cytokine signalling with a particular interest in mechanisms underlying normal and pathogenic JAK kinase activation.

Unit Directors

Director

Mark Daly

Mark Daly was appointed the FIMM Director with effect from February 1, 2018. He joined FIMM from the Broad Institute of MIT and Harvard and Massachusetts General Hospital. He is a distinguished scientist who has made major contributions to human genetics and genomics during his 20-year career.

To contact Mark Daly, please e-mail to: fimm-director@helsinki.fi, or contact Susanna Rosas.

Vice Director

Samuli Ripatti

Professor Samuli Ripatti has been appointed as Vice Director of the Institute for Molecular Medicine Finland (FIMM) for the period 1 May 2019 – 31 December 2022.

The Vice Director supports the FIMM Director in the development of FIMM as a whole, and in the absence or disqualification of the director acts as his or her deputy. 

Samuli Ripatti is a Professor of Biometry at the Faculty of Medicine of the University of Helsinki and a Scholar at the Broad Institute of MIT and Harvard in Cambridge, MA, USA. Furthermore, he is the director of the Academy of Finland Centre of Excellence in Complex Disease Genetics. His research group studies genetic variation in the Finnish population and its effects on common complex disease risks and management. His research focuses in particular on cardiometabolic diseases as models to learn about disease mechanisms and genomic strategies for diagnoses and prevention. Samuli Ripatti has published over 250 articles that have been cited over 26,000 times. He is also currently chairing Doctoral Programmes in Biomedicine and Population Health.

To contact Samuli Ripatti, please e-mail or call to Sari Kivikko.

Director

Juha Huiskonen

Juha Huiskonen is the director of the Institute of Biotechnology and Professor of Structural Biology. 

Huiskonen’s research group - Laboratory of Structural Biology (LSB) – aims at understanding the structure and function of biological macromolecules and their complexes, such as molecular machines and viruses.

To contact Juha Huiskonen, please email to bi-director@helsinki.fi 

Vice Director

Maria Vartiainen

Maria Vartiainen is a research director at the Institute of Biotechnology and the scientific head of the Light Microscopy Unit (LMU) at BI.

Vartiainen’s research group studies the mechanisms that mediate the dynamic organization of the cell nucleus, with special emphasis on the role of actin in this process.

Director

Jari Koistinaho
Biomedicum 1, room B222b
P.O.Box 63, Haartmaninkatu 8
FI-00014 University of Helsinki
Phone +358 50 3789 207
jari.koistinaho@helsinki.fi

Vice Director

Satu Palva
P.O. Box 21, Haartmaninkatu 3
FI-00014 University of Helsinki
Phone:  +358 50 4484 742
satu.palva@helsinki.fi

Coordinator

Päivi Kleemola
Biomedicum 1, room A303b
P.O.Box 63
FI-00014 University of Helsinki
paivi.kleemola@helsinki.fi

HiLIFE Board

The duties of the Board

  • discuss the institute’s implementation plan as well as the human resources policy and budget contained in it;
  • discuss and resolve matters that the director has referred to the Board based on their  importance or far-reaching nature;
  • provide a statement on the appointment of Level 3 teaching and research personnel and Level 4 research directors for three year or a longer term;
  • decide on HiLIFE research programs based on evaluation;
  • submit a proposal on HiLIFE operative units  based on evaluation;
  • submit a proposal on members and chairperson of HiLIFE Scientific Council to the Rector and to appoint Scientific Advisory Boards when necessary;
  • submit a proposal on members and chairperson of HiLIFE Innovation and Corporate Relations Council to the Rector; and
  • provide a statement on life science research infrastructures based on evaluation.

According to the Rules of Procedure the board consists of 5-9 members representing high quality research. 1-2 members represent interaction partners of the university. HiLIFE personnel selects one member and a personal deputy. Doctoral students at the University of Helsinki select one member and a personal deputy for a two year term. 

HiLIFE Board 1.8.2020-31.7.2024

Members (deputies)

  • Vice-rector Jouni Hirvonen, chair (3/2022 onwards), (Vice-rector Tom Böhling)
  • Professor Johanna Björkroth, (Professor Vincenzo Cerullo)
  • Academy Professor Elina Ikonen, (Academy Professor Lauri Aaltonen)
  • Professor Jaakko Kangasjärvi, (Associate Professor Mari Pihlatie)
  • Professor Anne Pitkäranta, Director of research HUS, (Markku Mäkijärvi, Chief Medical Officer HUS (4/2019 onwards))
  • Research professor Merja Penttilä, VTT, (Research professor Hannu Fritze, LUKE)
  • MSc Tuomas Pylkkö (8/2020 - 7/2022), (MSc Lisa Gawriyski (8/2020 - 7/2022))
  • Dean Anne Remes (2/2022 onwards), (Professor Per-Henrik Groop)
  • Research director Markku Varjosalo, (Research expert Miia Dufva)
HiLIFE Scientific Council

The HiLIFE Scientific Council supports the HiLIFE Board and leadership in developing activities and scientific directions. The Council is appointed for four year terms and consists of 8-10 external internationally accomplished life science area researchers and leaders.

The duties of the Scientific Council are to 

  • evaluate HiLIFE activities and organization in the context of the University;
  • make initiatives and provide statements on HiLIFE's scientific direction; 
  • provide statements on competency of applicants for director and operative unit director positions; 
  • participate in the selection of HiLIFE tenure track assistant/associate professors and in evaluations for their continuation on the tenure track; 
  • submit a proposal on recipients of HiLIFE Fellow funding based on evaluation; 
  • provide a statement on applications for HiLIFE research programs (grand challenges); and 
  • submit proposals on the organization and funding of shared use life science research infrastructures.

HiLIFE Scientific Council 1 June 2022 - 31 December 2026

Chair: 

  • Professor Alan L. Schwartz, Washington University at St. Louis, US 

Members:

  • Research director Søren Brunak, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark  
  • Director Daniela Corda, National Research Council, Italy 
  • Director Josef Martin Penninger, Life Sciences Institute, University of British Columbia, Canada; Institute of Molecular Biotechnology of the Austrian Academy of Sciences IMBA, Austria 
  • Professor Mary Power, Department of Integrative Biology, UC Berkeley & Angelo Coast Range Reserve, US 
  • Professor Christine R. Rose, Institute of Neurobiology, Heinrich Heine University Duesseldorf, Germany 
  • President Kristiina Vuori, Sanford Burnham Prebys Medical Discovery lnstitute, La Jolla, US 
  • Professor (emeritus) Anthony Watts, Department of Biochemistry, University of Oxford, UK 
  • Director Detlef Weigel, Max Planck Institute in Developmental Biology, Tübingen, Germany 

Invited expert members:

Representatives of HiLIFE Units’ Scientific Advisory Boards (SAB) (until 31.12.2022, new representatives from newly appointed SABs are expected to join the Council in 2023) 

  • Marja Jäättelä (SAB of Institute of Biotechnology),  
  • Mikael Simons (SAB of Neuroscience Center), and  
  • Cornelia van Duijn (SAB of Institute for Molecular Medicine Finland FIMM) 

Alumni:

  • Rector Ole Petter Ottersen, Karolinska Institutet (SC Chair 5/2017-4/2022)
  • Professor Anne-Claude Gavin;  Department for Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva (5/2017-4/2022)
  • Director Fiona Watt,  Centre for Stem Cells & Regenerative Medicine, King's College London (5/2017-5/2018)
  • Senior Pro Vice Chancellor Duncan Maskell, Cambridge University (5/2017-5/2019)
  • Professor Anders Björklund, Wallenberg Neuroscience Center, Lund University (5/2017-12/2018; SAB of the Neuroscience Center)
  • Director Emeritus Kai Simons, Max Planck Institute Cell Biology and Genetics (5/2017-12/2018; SAB of the Institute for Molecular Medicine Finland FIMM) 
Scientific Advisory Boards of the Units

The FIMM SAB consists of seven internationally recognized experts in the institute's fields of research and technological activities. 

SAB visits FIMM every two years. Based on the visit and documentation provided beforehand, the SAB prepares an evaluation report.

Composition

1 Janu­ary 2019 – 31 Decem­ber 2022

Chair

Professor Cornelia van Duijn, Erasmus MC, University Medical Center Rotterdam (NL)

Members
  • Professor Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala University, Sweden
  • Scientific director and professor, Nadia Rosenthal, The Jackson Laboratory for Genomic Medicine, US, and Imperial College London, UK
  • Professor Ramnik Xavier, Massachusetts General Hospital (MGH) and Broad Institute of MIT and Harvard, US
  • Professor Anant Madabhushi, Case Western Reserve University, Cleveland, USA
  • Professor Pasi Jänne, Dana-Farber Cancer Institute and Harvard Medical School, US
  • Professor Nuria Lopez Bigas, Institute for Research in Biomedicine, Barcelona, Spain
  • Group leader Jan Korbel, European Molecular Biology Laboratory (EMBL) Heidelberg, Germany

Composition

  • Director Ewan Birney, European Bioinformatics Institute EMBL-EBI, UK (Chair)
  • Professor Marja Jäättelä, University of Copenhagen, Denmark 
  • Professor Urban Lendahl, Karolinska Institutet, Sweden
  • Professor Poul Nissen, Aarhus University, Denmark
  • Professor Olivier Pourquié, Harvard Medical School and Brigham and Women’s Hospital, US 
  • Professor Anne Spang, University of Basel, Switzerland 
  • Professor Joan Steitz, Yale School of Medicine and HHMI, US
  • Professor Miltos Tsiantis, Max Planck Institute for Plant Breeding Research, Germany 

Alumni

  • Professor Sheena Radford, The Astbury Centre for Structural Molecular Biology, University of Leeds (01/2019-10/2020)

Composition

1 January 2019 – 31 December 2022:

  • Professor Mikael Simons, Institute of Neuronal Cell Biology (TUM-NCB), TU Munich and German Center for Neurodegenerative Diseases Munich (DZNE), Germany (chair)
  • Professor Anders Björklund, Developmental and Regenerative Neurobiology, Lund University, Sweden
  • Professor Sandra Ceccatelli, Department of Neuroscience, Karolinska Institute, Sweden
  • Professor Catherine Tallon-Baudry, Laboratoire de Neurosciences Cognitives et Computationnelles, Département d'études cognitives, Ecole Normale Supérieure (ENS), PSL Research University, INSERM, Paris, France
  • Professor Rita Horvath, Department of Clinical Neurosciences, University of Cambridge, UK